Literature DB >> 32474905

HBV-specific CD8 T cells present higher TNF-α expression but lower cytotoxicity in hepatocellular carcinoma.

L Zhao1, Y Jin2, C Yang2, C Li3.   

Abstract

Tumor necrosis factor (TNF)-α is largely regarded as a proinflammatory cytokine, but several recent researches have demonstrated that TNF-α could possess immunoregulatory roles with potential to suppress anti-tumor immunity. Chronic hepatitis B virus (HBV) infection is a major risk factor of hepatocellular carcinoma (HCC), and HBV-specific CD8 T cells could exert anti-tumor roles in HCC patients. Here, we found that HBV-specific CD8 T cells, both in the peripheral blood and in the tumor microenvironment, were more enriched with TNF-α-expressing cells than interferon (IFN)-γ-expressing cells. Compared to IFN-γ-expressing HBV-specific CD8 T cells, TNF-α-expressing HBV-specific CD8 T cells presented lower expression of inhibitory checkpoint molecules, including programmed cell death (PD)-1, T cell immunoglobulin mucin-3 (TIM-3) and cytotoxic T lymphocyte antigen (CTLA)-4. HBV-specific CD8 T cells could mediate the lysis of autologous primary tumor cells, and the inhibition of TNF-α could further elevate their cytotoxic capacity. Subsequently, we demonstrated that TNF-α inhibition in HBV-specific CD8 T cells could significantly increase granzyme B (GZMB) and perforin 1 (PRF1) expression while having no effect towards granzyme A (GZMA) expression. The addition of exogenous TNF-α at low levels had no consistent effect on the expression of GZMA, GZMB and PRF1, but at higher levels, exogenous TNF-α significantly reduced GZMA, GZMB and PRF1 expression. Overall, these results suggested that TNF-α-expressing cells probably presented a deleterious role in HCC but were enriched in HBV-specific CD8 T cells.
© 2020 British Society for Immunology.

Entities:  

Keywords:  CD8 T cell; HBV; TNF-α; hepatocellular carcinoma

Year:  2020        PMID: 32474905      PMCID: PMC7419913          DOI: 10.1111/cei.13470

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  26 in total

1.  Rapid production of TNF-alpha following TCR engagement of naive CD8 T cells.

Authors:  Michael A Brehm; Keith A Daniels; Raymond M Welsh
Journal:  J Immunol       Date:  2005-10-15       Impact factor: 5.422

Review 2.  Immunological landscape and immunotherapy of hepatocellular carcinoma.

Authors:  Jesús Prieto; Ignacio Melero; Bruno Sangro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-10-20       Impact factor: 46.802

3.  Targeted Cancer Therapy with Tumor Necrosis Factor-Alpha.

Authors:  Weibo Cai; Zachary J Kerner; Hao Hong; Jiangtao Sun
Journal:  Biochem Insights       Date:  2008-07-22

Review 4.  Tumor necrosis factor and cancer, buddies or foes?

Authors:  Xia Wang; Yong Lin
Journal:  Acta Pharmacol Sin       Date:  2008-11       Impact factor: 6.150

5.  HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered Immune Tolerant.

Authors:  William S Mason; Upkar S Gill; Samuel Litwin; Yan Zhou; Suraj Peri; Oltin Pop; Michelle L W Hong; Sandhia Naik; Alberto Quaglia; Antonio Bertoletti; Patrick T F Kennedy
Journal:  Gastroenterology       Date:  2016-07-22       Impact factor: 22.682

6.  Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection.

Authors:  Carolina Boni; Paola Fisicaro; Caterina Valdatta; Barbara Amadei; Paola Di Vincenzo; Tiziana Giuberti; Diletta Laccabue; Alessandro Zerbini; Albertina Cavalli; Gabriele Missale; Antonio Bertoletti; Carlo Ferrari
Journal:  J Virol       Date:  2007-02-07       Impact factor: 5.103

7.  TNF-α and TGF-β counter-regulate PD-L1 expression on monocytes in systemic lupus erythematosus.

Authors:  Jing-Ni Ou; Alice E Wiedeman; Anne M Stevens
Journal:  Sci Rep       Date:  2012-03-02       Impact factor: 4.379

8.  The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection.

Authors:  M K Maini; C Boni; C K Lee; J R Larrubia; S Reignat; G S Ogg; A S King; J Herberg; R Gilson; A Alisa; R Williams; D Vergani; N V Naoumov; C Ferrari; A Bertoletti
Journal:  J Exp Med       Date:  2000-04-17       Impact factor: 14.307

Review 9.  Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations.

Authors:  Yingjun Xie; Yien Xiang; Jiyao Sheng; Dan Zhang; Xiaoxiao Yao; Yongsheng Yang; Xuewen Zhang
Journal:  J Immunol Res       Date:  2018-03-26       Impact factor: 4.818

Review 10.  HBV-Induced Immune Imbalance in the Development of HCC.

Authors:  Yongyan Chen; Zhigang Tian
Journal:  Front Immunol       Date:  2019-08-27       Impact factor: 7.561

View more
  3 in total

1.  Preclinical PET Imaging of Granzyme B Shows Promotion of Immunological Response Following Combination Paclitaxel and Immune Checkpoint Inhibition in Triple Negative Breast Cancer.

Authors:  Tiara S Napier; Chanelle L Hunter; Patrick N Song; Benjamin M Larimer; Anna G Sorace
Journal:  Pharmaceutics       Date:  2022-02-18       Impact factor: 6.321

2.  Prognostic signature for hepatocellular carcinoma based on 4 pyroptosis-related genes.

Authors:  Sainan Duan; Jianying Gao; Weiming Lou; Yize Zhang; Ying Deng; Cong Wang; Haiyue Huang; Hui Xu; Sixuan Guo; Shuhui Lai; Feiyang Xi; Zhangwang Li; Libin Deng; Yuanbin Zhong
Journal:  BMC Med Genomics       Date:  2022-07-28       Impact factor: 3.622

3.  Arthrospira Enhances Seroclearance in Patients with Chronic Hepatitis B Receiving Nucleos(t)ide Analogue through Modulation of TNF-α/IFN-γ Profile.

Authors:  Sheng-Jie Shiue; Chao-Ling Cheng; Han-Shiang Shiue; Chun-Nan Chen; Sheng-Wei Cheng; Li-Wei Wu; Ganbolor Jargalsaikhan; Tze-Sian Chan; Hsin-Yi Lin; Ming-Shun Wu
Journal:  Nutrients       Date:  2022-07-06       Impact factor: 6.706

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.